Q3 2025 Rigel Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Rigel Pharmaceuticals Inc (RIGL) reported total revenue of $69.5 million for the third quarter of 2025, including record net product sales of $64.1 million, a 65% year-over-year increase.
- The company has raised its 2025 revenue guidance to $285 million to $290 million, reflecting anticipated growth of 55% to 59% compared to 2024.
- Rigel Pharmaceuticals Inc (RIGL) has completed enrollment in the dose escalation phase of its Phase 1B study of R289, with promising preliminary safety and efficacy data.
- The company is expanding access to its products internationally, with TAVALISSE now available in Japan, Europe, Canada, Israel, and South Korea.
- Rigel Pharmaceuticals Inc (RIGL) reported a net income of $27.9 million for the third quarter, significantly higher than the $12.4 million reported in the same period of 2024.
- The CNS disease program with Eli Lilly will be terminated, which may impact future collaboration opportunities in that area.
- There is uncertainty regarding the competitive positioning of R289 in lower-risk MDS, as it is still early to determine its potential against competitors like RYTELO.
- The company faces challenges in expanding its product portfolio through in-licensing and acquisitions, which are necessary for long-term growth.
- Rigel Pharmaceuticals Inc (RIGL) has not provided specific guidance on gross-to-net rates by product, which may lead to uncertainty in financial projections.
- The company is still evaluating options for a Rigel-led study in glioma, indicating potential delays in advancing this part of the development pipeline.
Greetings and welcome to the Rigel Pharmaceuticals's financial conference call for the third quarter of 2025.
(Operator Instructions) As a reminder, this conference is being recorded.
It is now my pleasure to introduce our first speaker, Ray Furey, Rigel's Executive Vice President, General Counsel, and Corporate Secretary. Thank you, Mr. Furey. You may begin.
Welcome to our third quarter of 2025 financial results and business update conference call.
The financial press release for the third quarter of 2025 was issued a short while ago and can be viewed, along with the slides for this presentation, in the News & Events section of our Investor Relations site on rigel.com.
As a reminder, during today's call, we may make forward-looking statements regarding our financial outlook and our plans and time for regulatory and product development. These statements are subject to risks and uncertainties that may cause actual
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
